<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01410058</url>
  </required_header>
  <id_info>
    <org_study_id>MO 001</org_study_id>
    <nct_id>NCT01410058</nct_id>
  </id_info>
  <brief_title>Moringa Oleifera- Antiretroviral Pharmacokinetic Drug Interaction</brief_title>
  <official_title>Effect of Moringa Oleifera (Moringa, Drumstick/Horseradish Tree) on The Pharmacokinetics of Efavirenz and Nevirapine In-vivo.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zimbabwe</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>State University of New York at Buffalo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Biomedical Research and Training Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Zimbabwe</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study will be conducted by scientists from the University of Zimbabwe to determine if
      antiretroviral drugs are affected by taking herbs at the same time. This is important because
      herbal medicines may interact with modern medicine to increase or decrease the amount of
      medication in the body.

      The drugs nevirapine and efavirenz will be studied. Both drugs are routinely used as part of
      combination therapy for treating HIV. In this study it will be determined whether the
      concentrations of the antiretroviral drugs nevirapine and efavirenz are low, high or are in
      the desired range when taken together with the herb moringa.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The use of herbal supplements is widespread in Africa, particularly for the management of HIV
      and AIDS. In Zimbabwe, the prevalence of herbal medicine use in HIV-infected people is as
      high as 79% (Sebit et al., 2000). Several studies have shown that the herb Moringa oleifera
      is among the top 10 herbs most commonly used by HIV-positive people in Zimbabwe (Makomeya et
      al 2004, Monera et al 2008). Another review also cited Moringa as one of the 53 most
      important African medicinal plants presently traded (van den Bout-van den Beukel et al 2006).
      Others included Hypoxis hemerocallidea (African potato) and Sutherlandia frutescens-(Cancer
      bush). Moringa is rich in β-carotene, protein, vitamin C, calcium and potassium and act as a
      good source of natural antioxidants (Anwar et al.,2007).It is recommended by non-governmental
      organisations and some African governments as an immune booster and a nutritional supplement
      for people living with HIV and AIDS (Ncube, 2006). Most advocates and users believe that
      since the herb is natural, it is free from all side effects and interactions.

      Concomitant use of herbs with conventional drugs may lead to herb-drug interactions in the
      same way that two or more co-administered drugs may interact. Herbal constituents that are
      substrates for the same enzymes or transporters of conventional drugs may induce or inhibit
      the enzymes and/or transporter activity. Pharmacokinetic endpoints such as area under the
      curve (AUC), time to maximum plasma concentration (tmax), peak plasma concentration (Cmax),
      trough concentration (Cmin), clearance (CL), volume of distribution (Vd/F) and half-life
      (T1/2) may be altered significantly resulting in toxicity, more severe adverse effects,
      sub-therapeutic drug concentrations, HIV resistance and treatment failure.The risk of
      interaction increases as the number of co-administered drugs increases (de Maat et al 2003).
      As a result, people taking herbal medicines while on antiretroviral therapy are at very high
      risk because of the multitude use of highly active antiretroviral drugs and treatment of
      opportunistic infections, and also because herbs contain a wide range of bioactive chemical
      constituents.

      However, evidence based information of such effects is usually lacking and as such; health
      practitioners' ability to make relevant clinical decisions is limited. Results of a review of
      in vitro studies suggest a need for in vivo metabolic drug-drug interaction studies (van den
      Bout-van den Beukel et al 2006). Preliminary in vivo studies in animal models can serve as a
      basis for clinical trials, the results of which are considered the gold standard in this era
      of evidence-based medicine.

      Primary objectives

        1. To compare the steady-state pharmacokinetics of nevirapine and efavirenz in HIV-positive
           patients before and after supplementation with Moringa oleifera leaf powder

        2. To compare the single dose pharmacokinetics of nevirapine and efavirenz in rat models
           before and after supplementation with Moringa oleifera leaf powder

           Secondary objectives

        3. To determine the bioavailability of Moringa oleifera leaf powder in humans after oral
           dosing using beta carotene as a bio marker.

        4. To compare urine chemistries and liver function tests in HIV patients before and after
           supplementation with Moringa oleifera leaf powder

        5. To determine the presence of any genetic variation in the participants in the genes that
           code for CYP3A4 and CYP2B6
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>Baseline (day 22), Post-moringa (day 35)</time_frame>
    <description>Area under the plasma concentration time curve, determined using a non-compartmental approach by means of the Phoenix WinNonlin software application. Time points for sample collection were 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 h</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>C12h</measure>
    <time_frame>Baseline (Day 22); Post-moringa (Day 35)</time_frame>
    <description>plasma concentration 12h post dose, determined using a non-compartmental approach by means of the Phoenix WinNonlin software application. Time points for sample collection were 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 h</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Cmax</measure>
    <time_frame>Baseline (day 22), Post-moringa (day 35)</time_frame>
    <description>Maximum plasma concentration post does, determined using a non-compartmental approach by means of the Phoenix WinNonlin software application. Time points for sample collection were 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 h</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">19</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Nevirapine</arm_group_label>
    <description>HIV positive patients on nevirapine containing regimen, taking Moringa oleifera leaf powder</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Efavirenz</arm_group_label>
    <description>HIV positive patients on efavirenz containing regimen, taking Moringa oleifera</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Moringa oleifera</intervention_name>
    <description>leaf powder, 1.85g once daily, hard gelatin capsules</description>
    <arm_group_label>Efavirenz</arm_group_label>
    <arm_group_label>Nevirapine</arm_group_label>
    <other_name>moringa</other_name>
    <other_name>drumstick tree</other_name>
    <other_name>horseradish tree</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz 600mg</intervention_name>
    <description>Efavirenz 600mg based regimen</description>
    <arm_group_label>Efavirenz</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nevirapine 200Mg Oral Tablet</intervention_name>
    <description>Nevirapine 200mg based regimen</description>
    <arm_group_label>Nevirapine</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood, plasma, urine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        HIV Opportunistic infections clinic
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV positive,

          -  ≥ 4 weeks on Nevirapine or , ≥ 2 weeks on Efavirenz containing regimen,

          -  Supplements HAART with Moringa oleifera.

        Exclusion Criteria:

        Known hepatic, intestinal or renal disease,smoking, chronic alcohol ingestion, poor venous
        access, chronic alcohol ingestion, pregnant, smoking, on rifampicin, ketoconazole,
        isoniazid, breastfeeding, anaemia,vomiting
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tsitsi G Monera, BPharmHons, MPhil, MSc CT</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Zimbabwe</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Parirenyatwa Hospital OI Clinic</name>
      <address>
        <city>Harare</city>
        <country>Zimbabwe</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Zimbabwe</country>
  </location_countries>
  <reference>
    <citation>Anwar F, Latif S, Ashraf M, Gilani AH. Moringa oleifera: a food plant with multiple medicinal uses. Phytother Res. 2007 Jan;21(1):17-25. Review.</citation>
    <PMID>17089328</PMID>
  </reference>
  <reference>
    <citation>Sebit MB, Chandiwana SK, Latif AS, Gomo E, Acuda SW, Makoni F, Vushe J. Quality of life evaluation in patients with HIV-I infection: the impact of traditional medicine in Zimbabwe. Cent Afr J Med. 2000 Aug;46(8):208-13.</citation>
    <PMID>11317592</PMID>
  </reference>
  <reference>
    <citation>van den Bout-van den Beukel CJ, Koopmans PP, van der Ven AJ, De Smet PA, Burger DM. Possible drug-metabolism interactions of medicinal herbs with antiretroviral agents. Drug Metab Rev. 2006;38(3):477-514. Review.</citation>
    <PMID>16877262</PMID>
  </reference>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>August 3, 2011</study_first_submitted>
  <study_first_submitted_qc>August 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2011</study_first_posted>
  <results_first_submitted>August 23, 2017</results_first_submitted>
  <results_first_submitted_qc>March 29, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 2, 2019</results_first_posted>
  <last_update_submitted>March 29, 2019</last_update_submitted>
  <last_update_submitted_qc>March 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Zimbabwe</investigator_affiliation>
    <investigator_full_name>Tsitsi Grace Monera</investigator_full_name>
    <investigator_title>Lecturer</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>antiretroviral drug interaction</keyword>
  <keyword>herbal medicine</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>herbal pharmacology</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Nevirapine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>HIV-infected male and female adults reporting for routine HIV clinic visits at a referral hospital in Zimbabwe were identified through an interviewer-administered questionnaire.</recruitment_details>
      <pre_assignment_details>The study had a minimum 3-week herbal medication wash out period prior to the first dosing to reduce the possibility of carryover from any type of previously used moringa or other herbal medication, so the participants would have the same baseline.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Nevirapine</title>
          <description>HIV positive patients on nevirapine containing regimen, taking Moringa oleifera leaf powder</description>
        </group>
        <group group_id="P2">
          <title>Efavirenz</title>
          <description>HIV positive patients on efavirenz containing regimen, taking Moringa oleifera leaf powder</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Washout Day 0</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Baseline Day 22</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Day 35</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>11/13 were analysed in the nevirapine arm. 2 had missing data due to insufficient blood sample and were excluded from analysis.
6/6 were analysed for efavirenz arm</population>
      <group_list>
        <group group_id="B1">
          <title>Nevirapine</title>
          <description>HIV positive patients on nevirapine containing regimen, taking Moringa oleifera leaf powder
Moringa oleifera: leaf powder, 1.85g once daily as hard gelatin capsules</description>
        </group>
        <group group_id="B2">
          <title>Efavirenz</title>
          <description>HIV positive patients on efavirenz containing regimen, taking Moringa oleifera
Moringa oleifera: leaf powder, 1.85g once daily as hard gelatin capsules</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44" spread="8"/>
                    <measurement group_id="B2" value="43" spread="8"/>
                    <measurement group_id="B3" value="44" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.5" spread="7.5"/>
                    <measurement group_id="B2" value="72.5" spread="17.0"/>
                    <measurement group_id="B3" value="65.9" spread="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>AUC</title>
        <description>Area under the plasma concentration time curve, determined using a non-compartmental approach by means of the Phoenix WinNonlin software application. Time points for sample collection were 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 h</description>
        <time_frame>Baseline (day 22), Post-moringa (day 35)</time_frame>
        <population>Only participants with complete data were included</population>
        <group_list>
          <group group_id="O1">
            <title>Nevirapine</title>
            <description>HIV positive patients on nevirapine containing regimen, taking Moringa oleifera leaf powder
Moringa oleifera: leaf powder</description>
          </group>
          <group group_id="O2">
            <title>Efavirenz</title>
            <description>HIV positive patients on efavirenz containing regimen, taking Moringa oleifera
Moringa oleifera: leaf powder</description>
          </group>
        </group_list>
        <measure>
          <title>AUC</title>
          <description>Area under the plasma concentration time curve, determined using a non-compartmental approach by means of the Phoenix WinNonlin software application. Time points for sample collection were 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 h</description>
          <population>Only participants with complete data were included</population>
          <units>h*microgram/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.17" spread="25.24"/>
                    <measurement group_id="O2" value="34.67" spread="24.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-moringa (Day 35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.44" spread="27.65"/>
                    <measurement group_id="O2" value="32.58" spread="38.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>C12h</title>
        <description>plasma concentration 12h post dose, determined using a non-compartmental approach by means of the Phoenix WinNonlin software application. Time points for sample collection were 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 h</description>
        <time_frame>Baseline (Day 22); Post-moringa (Day 35)</time_frame>
        <population>Only patients with complete data were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Nevirapine</title>
            <description>HIV positive patients on nevirapine containing regimen, taking Moringa oleifera leaf powder
Moringa oleifera: leaf powder, 1.85g once daily as hard gelatin capsules</description>
          </group>
          <group group_id="O2">
            <title>Efavirenz</title>
            <description>HIV positive patients on efavirenz containing regimen, taking Moringa oleifera
Moringa oleifera: leaf powder, 1.85g once daily as hard gelatin capsules</description>
          </group>
        </group_list>
        <measure>
          <title>C12h</title>
          <description>plasma concentration 12h post dose, determined using a non-compartmental approach by means of the Phoenix WinNonlin software application. Time points for sample collection were 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 h</description>
          <population>Only patients with complete data were included in the analysis.</population>
          <units>microgram/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.30" spread="25.85"/>
                    <measurement group_id="O2" value="2.96" spread="18.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-moringa (Day 35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.55" spread="28.56"/>
                    <measurement group_id="O2" value="2.53" spread="21.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Cmax</title>
        <description>Maximum plasma concentration post does, determined using a non-compartmental approach by means of the Phoenix WinNonlin software application. Time points for sample collection were 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 h</description>
        <time_frame>Baseline (day 22), Post-moringa (day 35)</time_frame>
        <population>Only patients with complete data were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Nevirapine</title>
            <description>HIV positive patients on nevirapine containing regimen, taking Moringa oleifera leaf powder
Moringa oleifera: leaf powder</description>
          </group>
          <group group_id="O2">
            <title>Efavirenz</title>
            <description>HIV positive patients on efavirenz containing regimen, taking Moringa oleifera
Moringa oleifera: leaf powder</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax</title>
          <description>Maximum plasma concentration post does, determined using a non-compartmental approach by means of the Phoenix WinNonlin software application. Time points for sample collection were 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 h</description>
          <population>Only patients with complete data were included.</population>
          <units>microgram/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.92" spread="26.93"/>
                    <measurement group_id="O2" value="5.08" spread="22.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-moringa (Day 35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.57" spread="29.62"/>
                    <measurement group_id="O2" value="5.51" spread="38.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected at baseline (day 22) and at final visit (day 35).</time_frame>
      <desc>All participants were monitored for adverse events throughout the study. The study medical officer documented any adverse events observed from clinical examinations or self-reported by the participants at each of the two visits. Urinalysis and Serum biochemistries were determined and graded based on CTCAE.</desc>
      <group_list>
        <group group_id="E1">
          <title>Nevirapine</title>
          <description>HIV positive patients on nevirapine containing regimen, taking Moringa oleifera leaf powder
Moringa oleifera: leaf powder, 1.85g once daily as hard gelatin capsules</description>
        </group>
        <group group_id="E2">
          <title>Efavirenz</title>
          <description>HIV positive patients on efavirenz containing regimen, taking Moringa oleifera
Moringa oleifera: leaf powder, 1.85g once daily as hard gelatin capsules</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated liver transaminase</sub_title>
                <description>greater than upper limit of normal - 3 times upper limit of normal</description>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="13"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Altered creatinine clearance</sub_title>
                <description>Creatinine clearance outside range 88-137 mL/min</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Tsitsi G Monera-Penduka</name_or_title>
      <organization>University of Zimbabwe College of Health Sciences</organization>
      <phone>307148</phone>
      <email>moneratg@yahoo.co.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

